Post-Marketing Surveillance of the Transiderm-Nitro Patch in General Practice

Abstract

Post-Marketing Surveillance (PMS) of Transiderm-Nitro, a new transdermal form of nitroglycerin, was undertaken during the 6 months following its introduction to general practitioners in the United Kingdom. Two thousand four hundred and seventy-five record forms were received. Excluding the fourteen patients who died during the surveillance, treatment in the remaining 2461 was judged as effective in 80·6% of patients and was well tolerated, with 70·5% having no unwanted effects. The incidences of withdrawal from Transiderm-Nitro in all patients analyzed were 5·7% due to headaches, 3·6% due to other unwanted effects and only 3·1% due to the treatment being judged as ineffective. This PMS confirms that Transiderm-Nitro is an effective, well tolerated addition to the therapy of angina pectoris.

Get full access to this article

View all access options for this article.

References

Garnier

(1982) Die Behandlung der Angina pectoris mit einem neuen transdermalen therapeutischen System von Nitroglycerin (Nitroderm-TTS) unter Praxisbedingungen. Schweiz. Rdsch. Med. (Praxis) 71, 511.

Georgopoulos

A G

Markis

Georgiadis

(1982) Therapeutic efficacy of a new transdermal system containing nitroglycerin. European Journal of Clinical Pharmacology, 22, 6, 481.

Inman

W H W

(1981a) Post-marketing surveillance of adverse drug reactions in general practice. I: Search for new methods. British Medical Journal 282, 1131.

Inman

W H W

(1981b) Post-marketing surveillance of adverse drug reactions in general practice. II: Prescription-event monitoring at the University of Southampton. British Medical Journal 282, 1216.

Letzel

Johnson

K C

Kusus

(1982) Die Behandlung der Angina Pectoris mit einem Nitroglycerinpflaster. Therapiewoche, 32, 48, 6053.

Letzel

Johnson

L C

(1983) Fortschritte in der Nitrattherapie bei Koronarer Herzkrankheit. ZFA (Stuttgart), 59, 17, 1022.

Royal College of General Practitioners' Medicines Surveillance Organisation (1983) Monitoring of drugs after marketing. Journal of the Royal College of General Practitioners 33, 438.